Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revaree vs Estrace in Genitourinary Syndrome of Menopause
NCT04544475Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Randomised, open-label trial of Revaree in genitourinary syndrome of menopause (GSM) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Vulvovaginal Symptom Questionnaire at 12 weeks. Started Sep 2021; status: completed.
02
Drugs
Revaree
03
Conditions
genitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT04544475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544475.